NIH Backs Skull Implant to Bypass Brain's Fortress, Fight Cancer

BALTIMORE, MD – June 29, 2026 – In a significant boost for neurotechnology, CraniUS Therapeutics has secured a major award from the National Institutes of Health (NIH) to advance a novel device designed to outsmart one of medicine's most formidable obstacles: the blood-brain barrier. The Baltimore-based company received an initial $1.1 million, with the potential for up to $4 million in total, from the prestigious NIH Blueprint MedTech Optimizer Program.

This non-dilutive funding is aimed squarely at accelerating the company's NeuroPASS™ platform—a refillable, skull-embedded implant—toward its first-in-human clinical trial. The initial target is recurrent glioblastoma (GBM), the most aggressive and common form of brain cancer in adults, a disease for which the prognosis has remained tragically poor for decades.

The Glioblastoma Gauntlet

Glioblastoma treatment is a brutal race against time. The current standard of care, established nearly two decades ago, involves a multi-pronged attack of surgical resection, followed by radiation and chemotherapy. Yet, the tumor’s invasive, tentacle-like nature makes complete removal impossible. Microscopic cancer cells inevitably remain, leading to recurrence in almost all cases.

When glioblastoma returns, the outlook is grim, with a median overall survival of just six to nine months. A primary culprit for this therapeutic failure is the blood-brain barrier (BBB), a sophisticated network of blood vessels and tightly packed cells that acts as the brain's elite security detail. While it excels at protecting the brain from toxins and pathogens, it also blocks more than 98% of potential therapeutic drugs from reaching their intended target in effective concentrations. This biological fortress turns the brain into a privileged sanctuary, tragically shielding tumors from the very medicines designed to destroy them.

"The blood-brain barrier remains one of the greatest challenges in medicine," said Dr. Chad Gordon, Founder and Executive Chairman of CraniUS Therapeutics and Director of Neuroplastic and Reconstructive Surgery at Johns Hopkins. "Our vision is to create a practical, repeatable way to deliver therapies directly to the brain."

A New Key to the Brain's Kingdom

The NeuroPASS platform is CraniUS's answer to this challenge. It is not a new drug, but a new delivery system—a piece of sophisticated infrastructure designed to grant long-term, reliable access to the brain. The device itself is a fully implantable and programmable pump, ingeniously designed to be embedded within the temporal region of the skull, a space Dr. Gordon identified as ideal for housing such technology through his pioneering work in neuroplastic surgery.

This isn't a simple port. NeuroPASS is a refillable system with a concealed port, allowing for outpatient dosing over extended periods. It utilizes a method known as convection-enhanced delivery (CED), using gentle pressure to infuse therapies directly into brain tissue via tiny catheters. This approach allows for high, localized drug concentrations at the tumor site while minimizing the systemic toxicity and side effects that often accompany powerful chemotherapy drugs circulating throughout the body.

This design—combining long-term implantation, direct delivery, and outpatient refilling—positions NeuroPASS as a potential paradigm shift. It aims to transform cranial implants from passive, reconstructive hardware into an active, therapeutic interface.

The Power of the NIH Blueprint

Securing the NIH Blueprint MedTech award is more than just a financial milestone; it's a powerful vote of confidence from one of the world's foremost medical research agencies. The program acts as a specialized incubator, providing not only non-dilutive capital but also crucial access to a network of experts in engineering, preclinical testing, and regulatory strategy. Its goal is to de-risk promising but complex medical devices, making them more attractive for the private investment needed to carry them through expensive clinical trials and to market.

"NIH Blueprint MedTech support provides critical resources that will help accelerate NeuroPASS toward clinical evaluation and positions CraniUS to engage strategic partners," said Michael Maglin, Chief Executive Officer of the company. "It reflects the importance of solving therapeutic access to the brain, and it strengthens our momentum at a pivotal stage of development."

This momentum builds on a strong financial foundation. The neurotech firm has already raised approximately $40 million across several rounds, including a $20 million Series B financing announced earlier in 2026, which is expected to fund operations into 2027. The NIH award further solidifies its position as it prepares for the immense costs and complexities of human trials.

Beyond the First Target: A Platform for the Future

While glioblastoma is the critical first indication, the company's vision extends far beyond a single disease. The true promise of NeuroPASS lies in its potential as a universal platform for central nervous system (CNS) therapeutics. Its ability to deliver a wide range of agents—from traditional small molecules to cutting-edge biologics, gene therapies, and cellular treatments—could unlock new treatment possibilities for a host of devastating neurological disorders currently stymied by the blood-brain barrier, including Alzheimer's, Parkinson's, and Huntington's disease.

"This award enables us to accelerate critical engineering, manufacturing, preclinical, and regulatory activities needed to prepare NeuroPASS for first-in-human evaluation," said Mark Wladkowski, the company's Chief Operations/Technology Officer. "While glioblastoma is our lead indication, our long-term vision is for NeuroPASS to become the standard infrastructure for delivering therapeutics across CNS disease states."

The path from the lab to the clinic is long, arduous, and heavily regulated. As an investigational device, NeuroPASS must still navigate extensive preclinical testing and a multi-phase clinical trial process under the watchful eye of the FDA before its safety and effectiveness can be established. However, with significant private backing and now the strategic support of the NIH, CraniUS Therapeutics is poised to take the next critical step in its mission to build a permanent gateway through the brain's formidable wall.